Mednax End Period Cash Flow from 2010 to 2025

MD Stock  USD 13.70  0.28  2.00%   
Mednax's End Period Cash Flow is increasing over the years with stable fluctuation. Overall, End Period Cash Flow is expected to go to about 93.5 M this year. During the period from 2010 to 2025 Mednax End Period Cash Flow annual values regression line had geometric mean of  54,223,528 and mean square error of 76374.7 T. View All Fundamentals
 
End Period Cash Flow  
First Reported
1995-12-31
Previous Quarter
19.4 M
Current Value
103.8 M
Quarterly Volatility
123.6 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Mednax financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mednax's main balance sheet or income statement drivers, such as Depreciation And Amortization of 32.6 M, Interest Expense of 24.4 M or Total Revenue of 1.5 B, as well as many indicators such as Price To Sales Ratio of 0.43, Dividend Yield of 0.0 or PTB Ratio of 1.01. Mednax financial statements analysis is a perfect complement when working with Mednax Valuation or Volatility modules.
  
Check out the analysis of Mednax Correlation against competitors.

Latest Mednax's End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Mednax Inc over the last few years. It is Mednax's End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mednax's overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Pretty Stable
   End Period Cash Flow   
       Timeline  

Mednax End Period Cash Flow Regression Statistics

Arithmetic Mean140,659,899
Geometric Mean54,223,528
Coefficient Of Variation196.85
Mean Deviation153,739,275
Median56,745,000
Standard Deviation276,891,295
Sample Variance76668.8T
Range1.1B
R-Value0.27
Mean Square Error76374.7T
R-Squared0.07
Significance0.32
Slope15,414,468
Total Sum of Squares1150031.8T

Mednax End Period Cash Flow History

202593.5 M
202484.2 M
202373.3 M
20229.8 M
2021387.4 M
20201.1 B
2019112.8 M

About Mednax Financial Statements

Mednax stakeholders use historical fundamental indicators, such as Mednax's End Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Mednax investors may analyze each financial statement separately, they are all interrelated. For example, changes in Mednax's assets and liabilities are reflected in the revenues and expenses on Mednax's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Mednax Inc. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow84.2 M93.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out the analysis of Mednax Correlation against competitors.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mednax. If investors know Mednax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mednax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.11)
Earnings Share
(2.34)
Revenue Per Share
24.174
Quarterly Revenue Growth
0.009
Return On Assets
0.0467
The market value of Mednax Inc is measured differently than its book value, which is the value of Mednax that is recorded on the company's balance sheet. Investors also form their own opinion of Mednax's value that differs from its market value or its book value, called intrinsic value, which is Mednax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mednax's market value can be influenced by many factors that don't directly affect Mednax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mednax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mednax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mednax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.